Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey

Objectives The Global Cardiometabolic Risk Profile in Patients with hypertension disease survey investigated the cardiometabolic risk profile in adult outpatients with hypertension in Europe according to the control of blood pressure (BP) as defined in the European Society of Hypertension and of the European Society of Cardiology (ESH/ESC) guidelines. Methods Data on BP control and cardiometabolic risk factors were collected for 3370 patients with hypertension in 12 European countries. Prevalence was analyzed according to BP status and ATP III criteria for metabolic syndrome. Results BP was controlled (BP < 140/90 mmHg for nondiabetic patients; BP < 130/80 mmHg for diabetic patients) in 28.1% of patients. Patients with uncontrolled BP had significantly higher mean weight, BMI, waist circumference, fasting blood glucose, total cholesterol and triglycerides and high-density lipoprotein cholesterol levels were significantly lower (women only) compared with patients with controlled BP (P < 0.05). The prevalence of metabolic syndrome and type 2 diabetes was also significantly higher in patients with uncontrolled BP compared with controlled BP (P < 0.001) (metabolic syndrome: 66.5 versus 35.5%; diabetes 41.1 versus 9.8%, respectively). 95.3% of patients with both metabolic syndrome and type 2 diabetes had uncontrolled BP. In a multivariate analysis, diabetes and metabolic syndrome were found to be associated with a high risk of poor BP control: odds ratio, 2.56 (metabolic syndrome); 5.16 (diabetes). Conclusion In this European study, fewer than one third of treated hypertensive patients had controlled BP. Metabolic syndrome and diabetes were important characteristics associated with poor BP control. Thus, more focus is needed on controlling hypertension in people with high cardiometabolic risk and diabetes.

[1]  N. Tada,et al.  The underlying mechanisms for development of hypertension in the metabolic syndrome , 2008, Nutrition Journal.

[2]  T. MacDonald,et al.  Treatment patterns of hypertension and dyslipidaemia in hypertensive patients at higher and lower risk of cardiovascular disease in primary care in the United Kingdom , 2007, Journal of Human Hypertension.

[3]  A. Dominiczak,et al.  2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. , 2007, Journal of hypertension.

[4]  G. Mancia,et al.  Blood pressure control in Italy: results of recent surveys on hypertension , 2007, Journal of hypertension.

[5]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[6]  M. Hanefeld,et al.  Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study , 2007, Cardiovascular diabetology.

[7]  Claude Lenfant,et al.  Clinical practice and recent recommendations in hypertension management – reporting a gap in a global survey of 1259 primary care physicians in 17 countries , 2007, Current medical research and opinion.

[8]  R. Stafford,et al.  Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. , 2007, Archives of internal medicine.

[9]  J. Redón,et al.  Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERIC‐HTA study , 2007, Blood pressure.

[10]  P. Elliott,et al.  Blood pressure and the global burden of disease 2000. Part II: Estimates of attributable burden , 2006, Journal of hypertension.

[11]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[12]  R. Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[13]  R. Kahn,et al.  The metabolic syndrome: time for a critical appraisal , 2005, Diabetologia.

[14]  Oscar H Franco,et al.  Blood Pressure in Adulthood and Life Expectancy With Cardiovascular Disease in Men and Women: Life Course Analysis , 2005, Hypertension.

[15]  G. Cerasola,et al.  Influence of metabolic syndrome on hypertension‐related target organ damage , 2005, Journal of internal medicine.

[16]  G. Leoncini,et al.  Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients , 2005, Journal of internal medicine.

[17]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[18]  F. Magrini,et al.  Metabolic syndrome and target organ damage in untreated essential hypertensives , 2004, Journal of hypertension.

[19]  E. Mannarino,et al.  Prognostic value of the metabolic syndrome in essential hypertension. , 2004, Journal of the American College of Cardiology.

[20]  R. Cooper,et al.  Hypertension Treatment and Control in Five European Countries, Canada, and the United States , 2004, Hypertension.

[21]  S. Kiechl,et al.  Metabolic Syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study , 2003, International Journal of Obesity.

[22]  J. Luño,et al.  [Metabolic syndrome in patients with essential hypertension]. , 2003, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[23]  S. Priori,et al.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. , 2003, Journal of hypertension.

[24]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[25]  J. Real,et al.  Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. , 2003, European journal of internal medicine.

[26]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[27]  P. Nilsson,et al.  Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. , 2002, Diabetes & metabolism.

[28]  P. Lapuerta,et al.  Physician-related barriers to the effective management of uncontrolled hypertension. , 2002, Archives of internal medicine.

[29]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[30]  V. Pavlik,et al.  Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. , 2000, Archives of internal medicine.

[31]  Ward Hj.  Inadequate management of blood pressure in a hypertensive population. , 1999, The New England journal of medicine.

[32]  S. Kjeldsen,et al.  Clustering of coronary risk factors with increasing blood pressure at rest and during exercise , 1998, Journal of hypertension.

[33]  E. Michelson,et al.  Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. , 2005, American journal of hypertension.

[34]  D. Panagiotakos,et al.  Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. , 2004, American heart journal.

[35]  A. V. Vigoa,et al.  Síndrome metabólico en pacientes hipertensos esenciales , 2003 .

[36]  A. Zanchetti,et al.  European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension , 2003 .

[37]  R. Bergman,et al.  Utility of a surrogate measure of insulin resistance in American Indians: the Strong Heart Study. , 2002, Ethnicity & disease.